+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genital Herpes Treatment Market by Type, Clinical Trials, Route Of Administration, Drug Class, End User, Age Group, Patient Gender - Global Forecast 2025-2030- Product Image
Genital Herpes Treatment Market by Type, Clinical Trials, Route Of Administration, Drug Class, End User, Age Group, Patient Gender - Global Forecast 2025-2030- Product Image
Sale

Genital Herpes Treatment Market by Type, Clinical Trials, Route Of Administration, Drug Class, End User, Age Group, Patient Gender - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6016198
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Genital Herpes Treatment Market grew from USD 2.08 billion in 2023 to USD 2.17 billion in 2024. It is expected to continue growing at a CAGR of 4.80%, reaching USD 2.90 billion by 2030.

The genital herpes treatment market encompasses a range of pharmaceutical and therapeutic interventions aimed at managing and alleviating symptoms, preventing outbreaks, and reducing transmission of the herpes simplex virus. Necessitated by the high global prevalence and recurrent nature of the infection, treatments include antiviral medications such as acyclovir, valacyclovir, and famciclovir. The primary end-users are healthcare providers, hospitals, and individuals diagnosed with genital herpes. Key market growth drivers include an increasing awareness of sexually transmitted infections, advancements in biologic and molecular therapies, and a growing emphasis on improving quality of life for affected individuals. As more people access digital health information, demand for effective treatments and personalized medical guidance is on the rise. Potential opportunities lie in developing vaccines, innovative drug delivery systems, and leveraging telemedicine for patient management. Market players are encouraged to invest in R&D for new compound discoveries, engage in strategic partnerships for technology advancements, and develop affordable treatment alternatives to address diverse economic settings.

However, this market faces significant challenges, including the social stigma surrounding genital herpes that impacts treatment access and adherence, alongside regulatory hurdles related to drug approvals. Additionally, financial constraints in low-income regions restrict access to advanced treatments. The continuous emergence of drug-resistant strains of the virus further complicates treatment landscapes. Innovation should focus on the creation of long-acting therapeutics, potential curative treatments, and enhanced diagnostic tools for more precise and early interventions. Continuous educational campaigns are crucial to reduce stigma and enhance disease management strategies. As the market evolves, understanding patient demographic shifts, regulatory environments, and competitive landscapes will be essential for stakeholders aiming to position themselves effectively. Robust marketing strategies and patient engagement programs are imperative to breaking barriers and driving market expansion, with holistic approaches seeking to integrate patient education, preventative measures, and treatment solutions into comprehensive care models.

Understanding Market Dynamics in the Genital Herpes Treatment Market

The Genital Herpes Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
    • The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
    • Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
    • Growing importance of personalized medicine in tailoring treatments for genital herpes patients
  • Market Restraints
    • Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
  • Market Opportunities
    • Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
    • Integrating comprehensive sexual health education into treatment plans for genital herpes
    • Expanding genomic research to develop personalized treatment options for genital herpes patients
  • Market Challenges
    • Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment

Exploring Porter’s Five Forces for the Genital Herpes Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Genital Herpes Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Genital Herpes Treatment Market

External macro-environmental factors deeply influence the performance of the Genital Herpes Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Genital Herpes Treatment Market

The Genital Herpes Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Genital Herpes Treatment Market

The Genital Herpes Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Genital Herpes Treatment Market

The Genital Herpes Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genital Herpes Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Vertex Pharmaceuticals, and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Genital Herpes Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Antiviral Medications
      • Acyclovir
      • Famciclovir
      • Valacyclovir
    • Supplements
    • Topical Creams/Ointments
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
  • Drug Class
    • Antiviral
    • Immune Modulators
  • End User
    • Clinics
    • Homecare Settings
    • Hospitals
    • Pharmacies
  • Age Group
    • Adults
    • Geriatrics
    • Pediatrics
  • Patient Gender
    • Female
    • Male
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
5.1.1.2. The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
5.1.1.3. Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
5.1.1.4. Growing importance of personalized medicine in tailoring treatments for genital herpes patients
5.1.2. Restraints
5.1.2.1. Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
5.1.3. Opportunities
5.1.3.1. Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
5.1.3.2. Integrating comprehensive sexual health education into treatment plans for genital herpes
5.1.3.3. Expanding genomic research to develop personalized treatment options for genital herpes patients
5.1.4. Challenges
5.1.4.1. Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Genital Herpes Treatment Market, by Type
6.1. Introduction
6.2. Antiviral Medications
6.2.1. Acyclovir
6.2.2. Famciclovir
6.2.3. Valacyclovir
6.3. Supplements
6.4. Topical Creams/Ointments
7. Genital Herpes Treatment Market, by Clinical Trials
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
8. Genital Herpes Treatment Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
9. Genital Herpes Treatment Market, by Drug Class
9.1. Introduction
9.2. Antiviral
9.3. Immune Modulators
10. Genital Herpes Treatment Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Homecare Settings
10.4. Hospitals
10.5. Pharmacies
11. Genital Herpes Treatment Market, by Age Group
11.1. Introduction
11.2. Adults
11.3. Geriatrics
11.4. Pediatrics
12. Genital Herpes Treatment Market, by Patient Gender
12.1. Introduction
12.2. Female
12.3. Male
13. Americas Genital Herpes Treatment Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Genital Herpes Treatment Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Genital Herpes Treatment Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GENITAL HERPES TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GENITAL HERPES TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. GENITAL HERPES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. GENITAL HERPES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GENITAL HERPES TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GENITAL HERPES TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 63. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 65. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 66. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 105. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 107. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 108. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 113. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 115. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 116. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 129. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 131. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 132. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 177. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 178. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 179. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 180. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 202. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 203. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 204. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 205. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 210. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 212. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 213. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 226. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 228. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 234. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 236. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 250. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 251. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 252. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 253. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 282. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 284. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 285. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 290. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 292. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 293. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
TABLE 322. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 323. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 324. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 325. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 327. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 329. SPAIN GENITAL HERPES TREATMENT MARKET SI

Companies Mentioned

The leading players in the Genital Herpes Treatment Market, which are profiled in this report, include:
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Mylan
  • Novartis
  • Pfizer
  • Sanofi
  • Takeda Pharmaceutical
  • Teva Pharmaceutical Industries
  • Vertex Pharmaceuticals
  • ViiV Healthcare

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.17 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.9 Billion
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Herpes Genitalis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Herpes Genitalis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Herpes Treatment Market 2024-2028 - Product Image

Herpes Treatment Market 2024-2028

  • Report
  • 171 Pages
  • Global
From
Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Genital Herpes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 132 Pages
  • Global
From
Genital Herpes Market Report 2024 - Product Image

Genital Herpes Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Herpes Simplex - Pipeline Insight, 2024 - Product Image

Herpes Simplex - Pipeline Insight, 2024

  • Drug Pipelines
  • 75 Pages
  • Global
From

About the Genital Herpes Drug Market

The Genital Herpes Drug market is a subset of the larger Infectious Diseases Drugs market. Genital Herpes is a sexually transmitted infection caused by the herpes simplex virus (HSV). Treatment for genital herpes includes antiviral medications, which can reduce the severity and duration of symptoms. These drugs can also reduce the risk of transmitting the virus to others. Commonly prescribed medications include acyclovir, valacyclovir, and famciclovir. These drugs are available in both oral and topical forms. The Genital Herpes Drug market is highly competitive, with many companies offering similar products. Major players in the market include GlaxoSmithKline, Novartis, Merck, Pfizer, and Sanofi. Other companies include Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.